Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 64 of 64 entries
View as:

Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent

Phase: N/A Priority: Normal
NCT ID: NCT02431650 Org: User:
Start: 04/30/15 End: 09/30/16 Due: 09/30/17

Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01383096 Org: User:
Start: 04/30/12 End: 08/31/12 Due: 08/31/13

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.

Phase: N/A Priority: Normal
NCT ID: NCT04323306 Org: User:
Start: 08/12/20 End: 09/27/22 Due: 09/27/23

Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria

Phase: N/A Priority: Normal
NCT ID: NCT04368910 Org: User:
Start: 09/06/07 End: 11/15/10 Due: 11/15/11

Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate

Phase: N/A Priority: Normal
NCT ID: NCT01523002 Org: User:
Start: 01/31/12 End: 10/31/12 Due: 10/31/13

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT07011511 Org: User:
Start: 06/23/25 End: 12/02/27 Due: 12/02/28

Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01615822 Org: User:
Start: 08/31/12 End: 04/30/13 Due: 04/30/14

A Dose-escalation Study to Investigate Safety and Toleration of OZ439

Phase: N/A Priority: Normal
NCT ID: NCT01713608 Org: User:
Start: 11/30/12 End: 02/28/13 Due: 02/28/14

Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection

Phase: N/A Priority: Normal
NCT ID: NCT01213966 Org: User:
Start: 10/31/10 End: 05/31/12 Due: 05/31/13

First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367

Phase: N/A Priority: Normal
NCT ID: NCT05507970 Org: User:
Start: 07/29/22 End: 01/25/23 Due: 01/25/24

Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model

Phase: N/A Priority: Normal
NCT ID: NCT03195387 Org: User:
Start: 01/31/18 End: 12/31/18 Due: 12/31/19

A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265

Phase: N/A Priority: Normal
NCT ID: NCT02389348 Org: User:
Start: 02/28/15 End: 06/30/15 Due: 06/30/16

Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria

Phase: N/A Priority: Normal
NCT ID: NCT01594931 Org: User:
Start: 07/31/05 End: 04/30/06 Due: 04/30/07

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06558643 Org: User:
Start: 08/27/24 End: 08/31/25 Due: 08/31/26